1) Nadel S, Goldstein B, Williams MD, et al; REsearching severe Sepsis and Organ dysfunction in children: a gLobal perspective (RESOLVE) study group. Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial. Lancet 2007;369:836-43.
2) Inwald DP, Tasker RC, Peters MJ, et al; Paediatric Intensive Care Society Study Group (PICS-SG). Emergency management of children with severe sepsis in the United Kingdom: the results of the Paediatric Intensive Care Society sepsis audit. Arch Dis Child 2009;94:348-53.
3) Shime N, Kawasaki T, Saito O, et al. Incidence and risk factors for mortality in paediatric severe sepsis: results from the national paediatric intensive care registry in Japan. Intensive Care Med 2012;38:1191-7.
4) Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
5) 日本集中治療医学会Sepsis Registry委員会.日本版敗血症診療ガイドライン The Japanese Guidelines for the Management of Sepsis. 日集中医誌 2013;20:124-73.